Abstract 1615P
Background
Limited research has explored the prognostic factors in patients with mHSPC. Previous findings have shown that disease volume and metastatic diagnosis status are important prognostic factors for OS. We sought to develop and validate a prognostic model of OS in pts with mHSPC.
Methods
Data from 4 randomized phase III trials comparing treatment regimens (standard of care (SOC) vs SOC plus docetaxel) were utilized. OS was defined as time between date of randomization to date of death/or last follow-up. Variables with a missing rate less than 50% in at least one of the four trials were considered, including age, ECOG performance status (PS), radical prostatectomy, prior radiation therapy, Gleason score, site of metastases, number of bone metastases, opioid analgesic use, disease volume, M1 metastatic diagnosis, hemoglobin, albumin, PSA, and alkaline phosphatase. Multiple imputation was employed to handle missing values. We utilized two randomized trials (CHAARTED and GETUG-15) for developing the model. Additionally, we employed an ensemble proportional hazards model where the final model was constructed based on the augmented training set incorporating two risk scores from trial-specific models. We validated the fitted model using two comparisons from the STAMPEDE trial (SOC vs. SOC + docetaxel (A vs C) and SOC vs. SOC + zoledronic acid+ docetaxel (A vs E)). Model discrimination was assessed using the time-dependent area under the receiver operating characteristic curve (tAUC).
Results
This analysis included 2627 pts (1585 deaths) with median follow-up time of 60.3 months. Median age is 69 years, 72% of pts had ECOG PS of 0, 85% had de-novo metastases and 51% had high disease volume. Important prognostic factors of OS were disease volume, PS, radical prostatectomy, alkaline phosphatase and hemoglobin. The tAUCs in the two STAMPEDE testing sets and in the model with only the controls were 0.73 (95% CI, 0.71-0.77), 0.71 (95%CI, 0.67-0.74) and 0.73 (95%CI, 0.69-0.77), respectively.
Conclusions
The model identified novel prognostic factors of OS in men with mHSPC. It offers the potential for classifying pts into risk groups useful in selecting men in future mHSPC trials. Further validation of this prognostic model of OS is warranted.
Clinical trial identification
Data from four phase III trials are included in this analysis. GETUG 15 (NCT00104715), STAMPEDE (NCT00268476) and CHAARTED (NCT00309985).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Prostate Cancer Foundation Challenge Award, Prostate Cancer UK Research Innovation Award RIA16-ST2-020, National Institutes of Health Grants R01 CA256157 and R01 CA249279, the UKRI Medical Research Council Grant number: MC_UU_00004/06 and the United States Army Medical Research Award HT9425-23-1-0393.
Disclosure
S. Halabi: Financial Interests, Personal, Other, Member of DSMB: Sanofi, Aveo Oncology, BMS, Janssen, CG Oncology; Financial Interests, Institutional, Funding: ASCO; Financial Interests, Institutional, Coordinating PI, co-PI on Funded Research: Astellas. M.K. Parmar: Financial Interests, Institutional, Full or part-time Employment, Director at MRC Clinical Trials Unit at UCL: Medical Research Council Clinical Trials Unit at UCL; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca, Astellas, Janssen, Baxter, GSK; Financial Interests, Institutional, Research Grant: Clovis, Abcodia Pvt Ltd., Akagera, Amgen, Aspirin Foundation, Bayer, BMS US, Bri-BioCepheid, Cipla, CSL Behring, Eli Lilly, Emergent Biosolutions, Gilead Sciences, Grifols, Johnson & Johnson, Pfizer, Sanofi, ViiVHealthcare, Micronoma, Modus Theraputics, Mylan, Serum Institute of India, Shionogi, SyntenyBiotechnology, Takeda, Tibotec, Transgene, Virco and Xenothera; Non-Financial Interests, Advisory Role, Euro Ewing Consortium: University College London; Non-Financial Interests, Advisory Role, rEECur: University of Birmingham; Non-Financial Interests, Advisory Role, CompARE Trial: University of Birmingham; Non-Financial Interests, Advisory Role, ROSSINI Trial Platform: University of Birmingham. M.A. Carducci: Financial Interests, Personal, Advisory Board: Pfizer, Remedica, AstraZeneca; Financial Interests, Personal, Other, Data Safety Monitoring Board: Acrivon; Financial Interests, Personal, Other, JCO Editor: American Society of Clinical Oncology; Financial Interests, Institutional, Steering Committee Member: Arcus; Financial Interests, Institutional, Local PI: Celgene; Non-Financial Interests, Leadership Role: ECOG-ACRIN. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca, alliance Merck Pfizer, Bayer, EISAI; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, Ipsen, Bayer, EISAI; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS; Non-Financial Interests, Principal Investigator: Ipsen, BMS, Merck. N.D. James: Financial Interests, Personal, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial Interests, Personal, Advisory Board, Prostate cancer therapies: Janssen, Clovis, Novartis; Financial Interests, Institutional, Advisory Board, Assisted with submissions regarding licencing for abiraterone: Janssen; Financial Interests, Personal, Advisory Board, Docetaxel: Sanofi; Financial Interests, Institutional, Advisory Board, Providing STAMPEDE trial data to facilitate licence extensions internationally for docetaxel: Sanofi; Financial Interests, Personal, Advisory Board, Bladder cancer therapy: Merck; Financial Interests, Personal, Advisory Board, Advice around novel hormone therapies for prostate cancer: Bayer; Financial Interests, Personal, Invited Speaker, Lecture tour in Brazil August 2022 - speaking on therapy for advanced prostate cancer: Merck Sharp & Dohme (UK) Limited; Financial Interests, Institutional, Coordinating PI, Funding for STAMPEDE trial: Janssen, Astellas; Financial Interests, Institutional, Coordinating PI, Funding for RADIO trial bladder cancer: AstraZeneca. C. Sweeney: Financial Interests, Personal, Advisory Board, Consultancy: Genentech Roche, Bayer, Astellas, Pfizer, Pfizer, Sanofi, Lilly; Financial Interests, Personal, Other, Consultancy: Janssen, MSD; Financial Interests, Personal, Advisory Board: Point, Cellcentric; Financial Interests, Personal, Advisory Board, Consultant: Advancell; Financial Interests, Personal, Advisory Board, Advisory Boards: BMS; Financial Interests, Personal, Advisory Board, Consutlant: Amphista; Financial Interests, Personal, Stocks/Shares: Leuchemix; Financial Interests, Personal, Stocks/Shares, Consultant: Advancell; Financial Interests, Institutional, Advisory Board, Abiraterone plus cabozantinib: Exelixis; Financial Interests, Institutional, Research Grant: Bayer, Janssen, Astellas, Pfizer, Dendreon, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10